Immune Design, an early-stage biotech developing immunotherapy oncology treatments, announced terms for its IPO on Monday. The Seattle, WA-based company plans to raise $60 million by offering 4.7 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Immune Design would command a fully diluted market value of $221 million.
Immune Design, which was founded in 2008 and booked $1 million in licensing and product sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol IMDZ. Immune Design initially filed confidentially on April 24, 2014. Jefferies and Leerink Partners are the joint bookrunners on the deal.
